Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. [electronic resource]

By:

Bartlett, Nancy L

Contributor(s):

Smith, Mitchell R
Siddiqi, Tanya
Advani, Ranjana H
O'Connor, Owen A
Sharman, Jeff P
Feldman, Tatyana
Savage, Kerry J
Shustov, Andrei R
Diefenbach, Catherine S
Oki, Yasuhiro
Palanca-Wessels, Maria Corinna
Uttarwar, Mayur
Li, Martha
Yang, Jing
Jacobsen, Eric D

Producer: 20180112Description: 1607-1616 p. digitalISSN:

1029-2403

Subject(s):

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Biomarkers
Brentuximab Vedotin
Drug Resistance, Neoplasm
Female
Humans
Immunoconjugates -- administration & dosage
Immunohistochemistry
Ki-1 Antigen -- metabolism
Lymphoma, Large B-Cell, Diffuse -- diagnosis
Male
Middle Aged
Neoplasm Staging
Recurrence
Retreatment
Treatment Outcome
Young Adult

Online resources:

Available from publisher's website

In: Leukemia & lymphoma vol. 58

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

There are no comments on this title.

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.

APA

Bartlett N. L., Smith M. R., Siddiqi T., Advani R. H., O'Connor O. A., Sharman J. P., Feldman T., Savage K. J., Shustov A. R., Diefenbach C. S., Oki Y., Palanca-Wessels M. C., Uttarwar M., Li M., Yang J. & Jacobsen E. D. (20180112). Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. : Leukemia & lymphoma.

Chicago

Bartlett Nancy L, Smith Mitchell R, Siddiqi Tanya, Advani Ranjana H, O'Connor Owen A, Sharman Jeff P, Feldman Tatyana, Savage Kerry J, Shustov Andrei R, Diefenbach Catherine S, Oki Yasuhiro, Palanca-Wessels Maria Corinna, Uttarwar Mayur, Li Martha, Yang Jing and Jacobsen Eric D. 20180112. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. : Leukemia & lymphoma.

Harvard

Bartlett N. L., Smith M. R., Siddiqi T., Advani R. H., O'Connor O. A., Sharman J. P., Feldman T., Savage K. J., Shustov A. R., Diefenbach C. S., Oki Y., Palanca-Wessels M. C., Uttarwar M., Li M., Yang J. and Jacobsen E. D. (20180112). Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. : Leukemia & lymphoma.

MLA

Bartlett Nancy L, Smith Mitchell R, Siddiqi Tanya, Advani Ranjana H, O'Connor Owen A, Sharman Jeff P, Feldman Tatyana, Savage Kerry J, Shustov Andrei R, Diefenbach Catherine S, Oki Yasuhiro, Palanca-Wessels Maria Corinna, Uttarwar Mayur, Li Martha, Yang Jing and Jacobsen Eric D. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. : Leukemia & lymphoma. 20180112.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC